Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

NCT00098722 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

474

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Maraviroc (UK-427,857)
DRUG: optimized background therapy
DRUG: Maraviroc (UK-427,857)
DRUG: optimized background therapy
DRUG: optimized background therapy

Sponsor

ViiV Healthcare

Collaborators

[object Object]